EFPIA and APBI Give Statement on Brexit

June 24, 2016

EU and UK industry groups did their best to display calm and confidence as the world woke up to the reality of Brexit.

With markets waking up to the reality of Brexit, leading EU and UK industry organizations did their best to respond with calm and confidence. The European Federation of Pharmaceutical Industries (EFPIA) statement stressed a "patient-centric" mindset--a common goal "ensuring rapid access to innovation medicines" across Europe.

"As everyone involved in European healthcare considers the implications of the UK ’s decision to leave the European Union, EFPIA underscores the importance of ensuring that the patient is at the centre of all subsequent decisions.

EFPIA shares the common goal of ensuring rapid access to innovative medicines for patients across Europe, as well developing a regulatory and policy environment that fosters innovation and supports the research and development of new medicines to meet the needs of patients, healthcare systems and society. As an industry, over the coming months, we are committed to engaging with stakeholders both in Europe and in the UK to support these objectives."

Association of the British Pharmaceutical Industry's(ABPI) statement ensists on maintain a strong directive, that "the UK open for business"

​​Following the result of the United Kingdom's referendum on membership of the European Union, Mike Thompson, CEO of the Association of the British Pharmaceutical Industry (ABPI) has said:

"The voice of the British people has been heard. This creates immediate challenges for future investment, research and jobs in our industry in the UK. With that being the case, we are committed to working closely with the government to agree what steps need to be taken to send a strong signal that the UK is open for business."